Opus Genetics (IRD) Current Deferred Revenue (2019 - 2020)
Opus Genetics' (IRD) quarterly Current Deferred Revenue came in at $650000.0 in Q3 2020, down 56.67% year-on-year from $1.5 million in Q4 2019, and little changed on a QoQ basis from $650000.0 in Q2 2020.
Opus Genetics (IRD) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Opus Genetics (IRD) has 2 years of Current Deferred Revenue data on file, last reported at $650000.0 in Q3 2020.
- On a quarterly basis, Current Deferred Revenue fell 56.67% year-over-year to $650000.0 in Q3 2020; TTM through Sep 2020 was $650000.0, a 56.67% decrease from a year earlier, with the FY2019 full-year figure at $1.5 million, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2020 stood at $650000.0, roughly flat from $650000.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for IRD reached as high as $1.5 million in Q2 2019 and fell as low as $150000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 650,000.00 |
| Jun 30, 2020 | 650,000.00 |
| Mar 31, 2020 | 600,000.00 |
| Dec 31, 2019 | 1.50 Mn |
| Sep 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.50 Mn |
| Mar 31, 2019 | 150,000.00 |